Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Consolidation With Loncastuximab Tesirine After Immunochemotherapy in Relapsed/Refractory Mantle Cell Lymphoma
NCT05249959Phase 2Active, not recruiting
- Sponsor
- Fondazione Italiana Linfomi
- Start
- Mar 2022
- Primary completion
- Mar 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of loncastuximab tesirine in mantle cell lymphoma (MCL), sponsored by Fondazione Italiana Linfomi. Started Mar 2022; status: active, not recruiting.
02
Drugs
loncastuximab tesirine
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT05249959.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05249959.